Janney Montgomery Scott LLC Boosts Stock Position in Thermo Fisher Scientific Inc. $TMO

Janney Montgomery Scott LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.7% in the first quarter, HoldingsChannel.com reports. The fund owned 116,856 shares of the medical research company’s stock after purchasing an additional 14,086 shares during the period. Janney Montgomery Scott LLC’s holdings in Thermo Fisher Scientific were worth $57,439,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of TMO. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares in the last quarter. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $28,000. Swiss RE Ltd. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $28,000. Beacon Financial Strategies CORP acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $29,000. Finally, Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.1%

Shares of NYSE:TMO opened at $513.54 on Monday. The firm has a 50 day simple moving average of $474.08 and a 200-day simple moving average of $519.85. Thermo Fisher Scientific Inc. has a twelve month low of $401.45 and a twelve month high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $190.84 billion, a PE ratio of 28.23, a P/E/G ratio of 2.27 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same period last year, the business earned $5.15 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $605.09.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.